Revelation Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Rolke
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4660 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Nov 17, 2020
- CIK
- 0001810560
- Website
- revbiosciences.com
- Similar Companies
- Business
- Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage biopharmaceutical company that develops and commercializes therapies and diagnostics harnessing trained immunity through its proprietary Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD), a TLR4 agonist that reprograms the innate immune system to attenuate inflammatory responses. The company's core pipeline includes GEMINI-AKI, an intravenous therapy for preventing and treating acute kidney injury; GEMINI-CKD, targeting chronic kidney injury; GEMINI-PSI, aimed at preventing post-surgical infections; and earlier candidates such as REVTx-99b for allergic rhinitis and chronic nasal congestion, REVTx-200 as an intranasal immunomodulator vaccine adjuvant, and REVDx-501, a point-of-care diagnostic for respiratory viral infections. Founded in 2020 and headquartered in San Diego, California, Revelation Biosciences targets critical care and inflammatory disease markets primarily in the United States. Recent developments include announcement of positive top-line results from the Phase 1b PRIME clinical study of Gemini in chronic kidney disease patients in 2025, completion of patient dosing in that trial, securing $9.6 million in gross proceeds from a warrant inducement in September 2025, $4 million from a public offering in May 2025, and plans for an End-of-Phase 1 meeting with the FDA later in 2025 to discuss the clinical pathway for GEMINI-AKI.
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Viking Therapeutics (NASDAQ:VKTX) and Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences (NASDAQ:REVB) Shares Up 2.4% – Here’s Why
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year